Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) [A Branch of the Initial Treatment Domain of the SPIRIT-PCP Platform]

NCT07357103 is registered in ClinicalTrials.gov with McGill University Health Centre/Research Institute of the McGill University Health Centre as lead sponsor.

NCT NCT07357103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives) [A Branch of the Initial Treatment Domain of the SPIRIT-PCP Platform]
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase
Phase 4
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
September 30, 2029
Enrollment
416 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pneumocystis, pneumocystis carinii infection, pneumocystis carinii; infection, resulting from hiv disease, pneumocystis infection, pneumocystis jirovecii infection, pneumocystis jirovecii pneumonia, pneumocystosis associated with aids, pneumocystosis; pneumonia (etiology)